poisar

Filings · News reference

Seres Therapeutics Files Prospectus for Up To $300M Offering Of Common Stock, Preferred Stock, Debt, Warrants And Units

Benzinga Newsdesk

SERES THERAPEUTICS, INC.$300,000,000Common StockPreferred StockDebt SecuritiesWarrantsUnitsWe may offer and sell up to $300,000,000 in the aggregate of the securities identified above from time to time in one or more

More filings newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

MCRB
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026

    Seres Therapeutics announced preclinical data for SER-428, an investigational live biotherapeutic designed to reduce bloodstream infections in critically ill patients. The novel oral liquid formulation showed up to 1,000-fold reduction of pathogenic bacteria in preclinical models and builds on positive results from SER-155. The company is designing a Phase 1b trial in collaboration with Columbia University, with further development pending funding.

    MCRB